Diabetes

Adolescents with overweight or obesity and baseline HbA1c 6.3%-6.4% were at 72-fold greater risk for T2D than those with HbA1c of 5.5%, a new cohort study finds.

Remission of T2D, regardless of duration of remission, was associated with reduced risk of diabetes-related CKD and CVD in a post hoc analysis of Look AHEAD.

The digital prescription therapeutic when used along with prescription diabetes therapies, can help reduce the costs of managing the disease and enhance standard of care.

The GLP-1 RAs Wegovy, Ozempic, Mounjaro, and Zepbound have taken up more real estate on the US map in some areas than others. Click to find out more.

Your daily dose of the clinical news you may have missed.

Findings from new study suggest that promoting healthy coping strategies for stress during early life can reduce cardiometabolic risk, report researchers.

While the FDA's preliminary evaluation has not surfaced evidence of a link, the agency says it "cannot definitively rule out that a small risk may exist," and so will continue research.

Semaglutide was associated with a lower risk of first-time and recurrent suicidal ideations in patients with obesity or overweight or T2D, according to new study.

In an open letter to the public, Lilly decries use of tirzepatide products Mounjaro and Zepbound for nonmedical purposes and warns of counterfeit formulations.

Your daily dose of the clinical news you may have missed.

Cardiovascular mortality has been increasing among middle-aged US adult since 2011; a new study looked at changes in CV risk factors by income level over the past 20 years.

Your daily dose of the clinical news you may have missed.

Ndumele chairs the American Heart Association committee that characterized the syndrome and wrote the statement of evidence for its assessment and management.

AHA 2023: Semaglutide 2.4 mg reduced the risk of serious cardiovascular events by 20% in patients with obesity and overweight with established CVD but without diabetes, according to full SELECT trialresults.

The second GLP-1 mimetic-based drug approved for chronic weight management, tirzepatide may outperform semaglutide, the first.

NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.

Experts wrap up their discussion of emerging chronic kidney disease tests and treatments with key takeaways for providers and patients.

Robert Busch, MD, provides his approach on implementing artificial intelligence (AI) testing for chronic kidney disease and offers success stories of this testing and treatment approach.

Experts discuss a new artificial intelligence (AI) tool for earlier staging and management of chronic kidney disease (CKD). They also discuss several studies where this tool was utilized and its overall clinical significance.

Dhiren Patel, PharmD, and Robert Busch, MD, discuss emerging technologies to test and treat patients with chronic kidney disease (CKD) and why these treatments are currently being underutilized.

Experts highlight considerations for patients with chronic kidney disease and other comorbid conditions, particularly diabetes, in terms of screening and preventative care.

Experts discuss key challenges in testing and diagnosing a patient with chronic kidney disease, especially for those who are asymptomatic. In addition, they highlight new screening approaches to accurately identify these patients.

Your daily dose of the clinical news you may have missed.

A new paradigm for reducing CV morbidity and mortality provides a comprehensive approach to comorbid metabolic disease including early detection and treatment.

A novel study strongly suggests that pre-pregnancy obesity rather than associated adverse pregnancy outcomes is the "culprit" in postpartum heart disease.

Robert Busch, MD, discusses common screening methods to detect chronic kidney disease (CKD) and how he utilizes the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines in his practice.

Dhiren Patel, PharmD, and Robert Busch, MD, present an overview of chronic kidney disease (CKD) and how it may impact a patient.

The phase 3 semaglutide kidney outcomes trial will be stopped immediately with FLOW read out expected in early 2024, the company said.

Your daily dose of the clinical news you may have missed.

In adults older than age 65 years with T2D, a simple clinical decision support tool plus shared decision making reduced hypoglycemic episodes by half.